Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00040352 · ClinicalTrials.gov registry record

Clinical, Laboratory, and Epidemiologic Characterization of Individuals and Families at High Risk of Melanoma

A clinical trial of Melanoma and Dysplastic Nevus Syndrome, sponsored by National Cancer Institute (NCI).

Recruiting
Registry status
3,000
Enrollment target
2
Study locations

NCT00040352: Recruiting study of Melanoma and Dysplastic Nevus Syndrome, sponsored by National Cancer Institute (NCI).

NCT00040352 is a study of Melanoma and Dysplastic Nevus Syndrome that is actively recruiting participants, run by National Cancer Institute (NCI). The registered enrollment target is 3,000 participants, above the 695-participant average among 266 other Melanoma trials with a reported enrollment target (332% higher). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00040352, a study of Melanoma and Dysplastic Nevus Syndrome, is actively recruiting participants, sponsored by National Cancer Institute (NCI).

RECRUITING
Registry status
3,000 participants
Enrollment target
2
Study locations

Study Summary

This study will investigate how genetic and environmental factors contribute to the development of melanoma, a type of skin cancer, and related conditions. Individuals \>=4 weeks with a personal or family history of melanoma or atypical spitzoid/Spitz tumor may be eligible for this study. Participants will: * Fill out one or two questionnaires about their personal and family medical history. * Provide written consent for researchers to review their medical records and pathology materials related to their care and those of deceased relatives with melanomas, tumors, cancer, or other related illnesses for whom they are the next-of-kin or legally authorized representative. * Donate a blood or cheek cell sample to be used for genetic studies. (The blood sample is collected through a needle in an arm vein. The cheek cell sample is obtained either by gently brushing the inside of the mouth with a soft brush or by swishing a tablespoon of mouthwash and then spitting it into a container.) * Undergo a skin biopsy (removal of a small piece of skin tissue) for genetic study. For this procedure, the area of skin to be removed is numbed with a local anesthetic and a 1/4-inch piece of skin is excised with a cookie cutter-like instrument. The wound is then covered with a band-aid. Participants may be asked to travel to the NIH Clinical Center for evaluation, including a medical history, physical examination, and some of the following procedures: * Full body skin examination to evaluate the type and number of moles and document any evidence of sun damage to the skin. The examination involves all the skin from the scalp to the bottoms of the feet. After the examination, a medical photographer will photograph the skin, with close-ups of skin lesions marked by the examiner. If there are parts of the skin the participant does not want examined or photographed, he or she can tell the examiner. * Blood draw of about 120 milliliters (4 ounces) or less * Skin biopsy * Cheek cell sample

Primary Outcome

1\. Identification of major susceptibility genes for melanoma and dysplastic nevi. 2. Prospective risk of melanoma after initial exam and melanoma education. 3. Mortality of melanoma in families. 4. Identification of other risk factors for familial melanoma. 5. Identification of other cancers in melanoma-prone individuals and families.

Study Locations (2)

Maryland

  • National Cancer Institute (NCI) - Bethesda
  • National Institutes of Health Clinical Center - Bethesda

Trial Details

FieldValue
Enrollment Target 3,000 participants
Start Date 2002-07-01
National Cancer Institute (NCI)

3,257 total trials

What NCT00040352 shows while recruiting

NCT00040352 is an observational study that tracks outcomes without assigning an intervention. Its 3,000 participants enrollment target places it among the larger protocols in the corpus, above the 695-participant average among 266 other Melanoma trials with a reported enrollment target (332% higher).

The record links to 2 conditions, with Melanoma appearing as the primary indexed condition, and to 0 interventions.

NCT00040352 reports a single indexed study location in Maryland.

Frequently Asked Questions

What is clinical trial NCT00040352 about?

NCT00040352 is a clinical study titled "Clinical, Laboratory, and Epidemiologic Characterization of Individuals and Families at High Risk of Melanoma". This study will investigate how genetic and environmental factors contribute to the development of melanoma, a type of skin cancer, and related conditions. Individuals \>=4 weeks with a personal or family history of melanoma or atypical spitzoid/Spitz tumor may be eligible for this study. Participa...

What is the current status of trial NCT00040352?

This trial is currently recruiting. The enrollment target is 3,000 participants. The study started on 2002-07-01.

What conditions does trial NCT00040352 study?

This clinical trial studies the following conditions: Melanoma, Dysplastic Nevus Syndrome.

Who is sponsoring clinical trial NCT00040352?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00040352 being conducted?

This trial has 2 study locations across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Melanoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00040352's enrollment target sits among peer trials

3,000 8th of 266 higher than 258 of 266 other Melanoma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Melanoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00004847 · 3,000 participants · Phase 1

    Diagnosis of Pheochromocytoma

  • NCT00478712 · 3,000 participants

    Hirschsprung Disease Genetic Study

  • NCT00579566 · 3,000 participants

    Novel Biochemical and Molecular Determinants for Soft Tissue Sarcoma

  • NCT00816114 · 3,000 participants

    Chart Review Study of Chronic Myelogenous Leukemia (CML) Patients Treated With Imatinib Outside of a Clinical Trial

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT00040352, the US trial registry maintained by the National Library of Medicine. NCT00040352 (large enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.